January 04, 2023
5 min watch
Save
Bendamustine lymphodepletion effective, safe as part of CAR-T for advanced lymphoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with relapsed or refractory non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.
The approach also appeared safe, with low incidence of high-grade neutropenia.
Healio spoke with researcher Saurabh Dahiya, MD, FACP, associate professor of medicine at Stanford Medicine, about the findings and their potential implications, particularly in light of an ongoing fludarabine shortage.
Published by:
Sources/Disclosures
Collapse
Source:
Bharadwaj S, et al. Abstract 4657. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Disclosures:
Dahiya reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.